SCHEMBL23534286

SCHEMBL23534286

NC(=O)C1CCN(C(=O)c2n[nH]c3ccc(-c4cccnc4F)cc23)CC1

nearest known ligand 0.55

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 12/20 0.55
▸ WNT1 P04628 10/20 0.55
▸ CLK2 P49760 1/20 0.53
▸ CLK3 P49761 1/20 0.53
▸ GRM4 Q14833 1/20 0.46
▸ RBP4 P02753 2/20 0.46
▸ GSK3B P49841 5/20 0.43
▸ KCNH2 Q12809 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29753971 1.00 DYRK1A (0.55) DYRK1AWNT1CLK2CLK3GRM4
SCHEMBL29753907 0.85 DYRK1A (0.59) DYRK1AWNT1CLK2CLK3GRM4
SCHEMBL23533911 0.85 DYRK1A (0.59) DYRK1AWNT1CLK2CLK3GRM4
SCHEMBL29754076 0.83 ALDH1A1 (0.48) DYRK1AWNT1GRM4
SCHEMBL28810246 0.83 ALDH1A1 (0.48) DYRK1AWNT1GRM4
SCHEMBL23533888 0.80 DYRK1A (0.53) DYRK1AWNT1CLK2CLK3
SCHEMBL29753964 0.80 DYRK1A (0.53) DYRK1AWNT1CLK2CLK3
SCHEMBL23533862 0.79 DYRK1A (0.69) DYRK1AWNT1CLK2CLK3GSK3B
SCHEMBL31123846 0.79 DYRK1A (0.69) DYRK1AWNT1CLK2CLK3GSK3B
SCHEMBL23534215 0.78 DYRK1A (0.67) DYRK1AWNT1CLK2CLK3GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250243181-A2 NOVEL INDAZOLE DERIVATIVE AND USE THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2025-07-31 — — US claimed
CN-114867718-A Novel indazole derivative and use thereof 韩国化学研究院 2022-08-05 — — CN claimed
WO-2021125802-A1 NOVEL INDAZOLE DERIVATIVE, AND USE THEREOF 한국화학연구원 2021-06-24 — — WO claimed
US-20250243181-A2 NOVEL INDAZOLE DERIVATIVE AND USE THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2025-07-31 — — US disclosed
US-20230116733-A1 NOVEL INDAZOLE DERIVATIVE AND USE THEREOF KOREA RESEARCH INSTITUTE OFCHEMICAL TECHNOLOGY (KR) 2023-04-13 — — US disclosed
EP-4079732-A1 NOVEL INDAZOLE DERIVATIVE, AND USE THEREOF Korea Research Institute of Chemical Technology (KR) 2022-10-26 — — EP disclosed
CN-114867718-A Novel indazole derivative and use thereof 韩国化学研究院 2022-08-05 — — CN disclosed
WO-2021125802-A1 NOVEL INDAZOLE DERIVATIVE, AND USE THEREOF 한국화학연구원 2021-06-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250243181-A2 NOVEL INDAZOLE DERIVATIVE AND USE THEREOF TRIB2, YAP1, IDO2 DYRK1A 573/4885WNT1 1444/4885CLK2 342/4885
US-20230116733-A1 NOVEL INDAZOLE DERIVATIVE AND USE THEREOF TRIB2, YAP1, IDO2 DYRK1A 573/4885WNT1 1444/4885CLK2 342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback